A hidden catch to Australia’s generous regime for extension of term of pharmaceutical patents is that requesting an extension of term can act as a trigger for re-examination.
The Australian Patent Office has...more
Data exclusivity is a term that refers to the period in which data supplied by the first applicant to register a pharmaceutical product cannot be used by a subsequent applicant to register an equivalent product. As this data...more
The Australian government’s review of IP law in relation to pharmaceuticals proposes changes to tackle imbalances.
The Australian pharmaceutical market is significant, servicing 23 million people, and is dominated by...more
Significant changes to Australian patent opposition proceedings arise under the new Regulations to the Intellectual Property Laws Amendment (Raising the Bar) Act 2012 that came into force on April 15, 2013....more